Business Context and Reporting Period
This Form 8-K, dated October 23, 2025, reports on ATAI Life Sciences N.V. (ATAI), a Dutch public company. The filing details amendments to the Share Purchase Agreement (SPA) regarding the proposed acquisition of Beckley Psytech Limited. The report also provides supplemental disclosures and reminders regarding the Extraordinary General Meeting scheduled to approve the transaction.
Key Financial Metrics and Transaction Terms
The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it focuses on the financial mechanics of the pending acquisition:
- Consideration Adjustment: The number of ATAI shares to be issued to Beckley Psytech shareholders is reduced by 1,221,712 shares on a pro-rata basis.
- Revised Share Count: The total number of ATAI shares to be distributed to Beckley Psytech shareholders or underlying Replacement Awards is now 103,823,190 shares.
- Advisor Compensation: 900,901 ATAI shares will be issued to Cantor Fitzgerald & Co. for financial advisory services. These shares are not subject to lock-up restrictions and will be registered for resale.
- Permitted Leakage: The definition of "Permitted Costs" was adjusted. Leakage related to Transaction Costs or Carve-out Costs up to $3,780,500 (increased from $2,000,000) will be settled via a pro-rata reduction in Consideration Shares rather than cash.
Material Changes Versus Prior Period
The filing represents a material amendment to the previously announced SPA dated June 2, 2025. Key changes include:
- Share Issuance Reduction: A reduction in the total consideration shares issued to sellers to account for specific leakages and advisor fees.
- Valuation Definition Update: The definition of "Buyer Share Price" was amended to be the higher of (i) the VWAP from January 1, 2025, to ten business days prior to the shareholder meeting, or (ii) the VWAP for the 30 trading days prior to that date.
- Leakage Thresholds: The aggregate threshold for costs/expenses related to the Acquisition or Carve-Out that qualify as permitted leakage was increased from $2,000,000 to $3,780,500.
- Optionholder Treatment: Clarification that Replacement Awards for vested and in-the-money options will be granted within five business days of Closing and are subject to lock-up provisions, with a potential 0.75% release for tax obligations.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The transaction remains contingent upon shareholder approval at the Extraordinary General Meeting. Shareholders must notify the company of their intent to attend by October 31, 2025. The lock-up period for consideration shares will terminate on the later of 60 days following the public announcement of Beckley Psytech's Phase 2b Clinical Trial results for BPL-003, the Closing date, or the termination of the SPA.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include:
- Failure to obtain required shareholder approvals.
- Failure to realize anticipated benefits of the transaction.
- Termination of the Share Purchase Agreement due to unsatisfied conditions.
- Impact of the transaction on ATAI's ability to retain key personnel.
Investor Verification Checklist
- Verify the final number of shares to be issued (103,823,190) and the impact of the 1,221,712 share reduction on dilution.
- Confirm the status of the Extraordinary General Meeting and the October 31, 2025, deadline for shareholder attendance notifications.
- Review the updated "Buyer Share Price" calculation methodology to understand potential valuation impacts.
- Monitor the Phase 2b Clinical Trial results for BPL-003, as this dictates the end of the lock-up period for consideration shares.
- Check the registration statement (Form S-4) filed on September 24, 2025, for the full text of the SPA and detailed risk factors.